| Literature DB >> 30641727 |
Sin Yee Tan1, Joyce Ling Mei Wong2, Yan Jinn Sim3, Su Sie Wong4, Safa Abdelgadir Mohamed Elhassan5, Sean Hong Tan6, Grace Pei Ling Lim7, Nicole Wuen Rong Tay8, Naveenya Chetty Annan9, Subrat Kumar Bhattamisra10, Mayuren Candasamy11.
Abstract
Type 1 and type 2 diabetes mellitus is a serious and lifelong condition commonly characterised by abnormally elevated blood glucose levels due to a failure in insulin production or a decrease in insulin sensitivity and function. Over the years, prevalence of diabetes has increased globally and it is classified as one of the leading cause of high mortality and morbidity rate. Furthermore, diabetes confers a huge economic burden due to its management costs as well as its complications are skyrocketing. The conventional medications in diabetes treatment focusing on insulin secretion and insulin sensitisation cause unwanted side effects to patients and lead to incompliance as well as treatment failure. Besides insulin and oral hypoglycaemic agents, other treatments such as gene therapy and induced β-cells regeneration have not been widely introduced to manage diabetes. Therefore, this review aims to deliver an overview of the current conventional medications in diabetes, discovery of newer pharmacological drugs and gene therapy as a potential intervention of diabetes in the future.Entities:
Keywords: Diabetes mellitus; Gene therapy; Oral hypoglycaemic agents; Stem cells; β-cells regeneration
Mesh:
Substances:
Year: 2018 PMID: 30641727 DOI: 10.1016/j.dsx.2018.10.008
Source DB: PubMed Journal: Diabetes Metab Syndr ISSN: 1871-4021